StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.79−0.08 (-0.27%)

Close on Nov 18, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

UroGen Pharma's price to book ratio was 18.2× on Jan 31, 2025, against 6.8× a year earlier. Over the last 5 years it ranged from 2.1× to 23.3×, with a median of 5.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jan 31, 202518.2×+0.6
2024Dec 31, 202417.6×−1.2
2022Apr 29, 202218.9×+12.1
2021Dec 31, 20216.8×+3.5
2020Dec 31, 20203.3×−0.0
2019Dec 31, 20193.3×−3.4
2018Dec 31, 20186.7×+1.4
2017Dec 29, 20175.3×–

More UroGen Pharma figures

See a number that looks wrong?